Aspira Women's Health Files 8-K

TL;DR

Aspira Women's Health filed an 8-K for financial statements/exhibits. No major news.

AI Summary

On October 24, 2024, Aspira Women's Health Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure related to the company's financial status. No specific material events or transactions were detailed in the provided excerpt.

Why It Matters

This filing serves as a public record of Aspira Women's Health Inc.'s financial disclosures, providing transparency to investors and stakeholders.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate material changes or risks.

Key Numbers

• 001-34810 — SEC File Number (Identifies the company's filing with the SEC.)
• 33-0595156 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• October 24, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• VERMILLION, INC. (company) — Former Company Name
• CIPHERGEN BIOSYSTEMS INC (company) — Former Company Name
• ABIOTIC SYSTEMS (company) — Former Company Name

FAQ

From the Filing

0001493152-24-042315.txt : 20241024 0001493152-24-042315.hdr.sgml : 20241024 20241024080033 ACCESSION NUMBER: 0001493152-24-042315 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20241024 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241024 DATE AS OF CHANGE: 20241024 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 241390752 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm false 0000926617 0000926617 2024-10-24 2024-10-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549       FORM 8-K       CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 24, 2024   Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-34810   33-0595156 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   12117 Bee Caves Road Building III Suite 100   Austin , Texas   78738 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 512 519-0400     (Former Name or Former Address, if Changed Since Last Report)       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWH   The Nasdaq Stock Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events.   On October 24, 2024, Aspira Women’s Health Inc. (the “Company”) issued a letter to its shareholders announcing that it has been selected by th